Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Caspofungin
Drug ID BADD_D00376
Description Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
Indications and Usage For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
Marketing Status Prescription
ATC Code J02AX04
DrugBank ID DB00520
KEGG ID D07626
MeSH ID D000077336
PubChem ID 2826718
NDC Product Code Not Available
Synonyms Caspofungin | Cancidas | MK 0991 | MK-0991 | MK0991 | Caspofungin MSD | L 743,872 | L-743,872 | L743,872 | L-743872 | L743872 | L 743872 | Caspofungin Acetate
Chemical Information
Molecular Formula C52H88N10O15
CAS Registry Number 162808-62-0
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood creatinine increased13.13.01.004--
Blood glucose increased13.02.02.002--Not Available
Blood lactate dehydrogenase increased13.04.02.0020.000276%
Blood magnesium decreased13.11.01.008--Not Available
Blood potassium decreased13.11.01.010--Not Available
Blood potassium increased13.11.01.011--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood sodium increased13.11.01.013--Not Available
Blood urea increased13.13.01.006--Not Available
Blood uric acid decreased13.02.04.004--Not Available
Blood uric acid increased13.02.04.001--Not Available
Blood urine13.13.02.011--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Bone pain15.02.01.001--
Bradycardia02.03.02.002--Not Available
Bronchopulmonary aspergillosis22.07.08.001; Available
Burning sensation17.02.06.001; Available
C-reactive protein increased13.09.01.0070.000276%Not Available
Carbon dioxide decreased13.02.01.012--Not Available
Cardiac arrest02.03.04.0010.000276%
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest22.02.06.007; Available
Cardiovascular disorder24.03.02.009; Available
Chest discomfort22.02.08.001;; Available
Chest pain22.02.08.003;; Available
Cholestasis09.01.01.0010.002115%Not Available
Coagulopathy01.01.02.001--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 10 Pages